WAYNE, Pa., July 10 /PRNewswire-FirstCall/ -- Escalon Medical Corp. today announced, for the third year in a row, its inclusion in FORTUNE Small Business’ top 100 fastest-growing small public companies in America. FORTUNE Small Business, in conjunction with Zacks Investment Research, evaluated publicly-traded companies with revenues of less than $200 million and a stock price of more than $1, and companies were chosen for their percentage growth in earnings, revenue, and stock performance over the past three years. Escalon was ranked 82nd overall in 2006.
Escalon Medical Corp.'s CEO, Richard J. DePiano commented, “We are pleased to be ranked in this well-regarded list for three consecutive years. This recognition reflects the efforts of a well-focused team and our continued commitment to being a leading resource to our customers.” In addition to this recognition by FSB, Escalon was recognized by Forbes Magazine as one of its “200 Best Small Companies” in November 2004.
The FSB 100 list appears in the July/August issue of FORTUNE Small Business and is available at FSB.com.
Founded in 1987, Escalon develops markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. Escalon seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the Escalon’s distribution capabilities. Escalon has headquarters in Wayne, Pennsylvania and manufacturing operations in Long Island, New York, New Berlin, Wisconsin, Dallas, Texas, Oxford, Connecticut and Barrow-in-Furness, U.K.
Note: This press release contains statements that are considered forward- looking under the Private Securities Litigation Reform Act of 1995, including statements about Escalon’s future prospects. They are based on the Escalon’s current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether Escalon is able to implement its growth and marketing strategies, improve upon the operations of Escalon’s business units, including the integration of Drew’s operations and any acquisitions it may undertake, if any, of which there can be no assurance, generate cash and identify, finance and enter into business relationships and acquisitions, uncertainties and risks related to new product development, commercialization, manufacturing and market acceptance of new products, marketing acceptance of existing products in new markets, the continuity of royalty revenue, litigation and non- recurring expenses, research and development activities, including failure to demonstrate clinical efficacy, delays by regulatory authorities, scientific and technical advances by Escalon or third parties, introduction of competitive products, third party reimbursement and physician training as well as general economic conditions. Further information about these and other relevant risks and uncertainties may be found in Escalon’s report on Form 10- K, and its other filings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.
Escalon Medical Corp.
CONTACT: Richard J. DePiano, Chairman and CEO, of Escalon Medical Corp.,+1-610-688-6830; or Joseph Calabrese of Financial Relations Board,+1-212-827-3772
